BR0113649A - Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres - Google Patents

Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres

Info

Publication number
BR0113649A
BR0113649A BR0113649-6A BR0113649A BR0113649A BR 0113649 A BR0113649 A BR 0113649A BR 0113649 A BR0113649 A BR 0113649A BR 0113649 A BR0113649 A BR 0113649A
Authority
BR
Brazil
Prior art keywords
testosterone
kits
combinations
mammal
compositions
Prior art date
Application number
BR0113649-6A
Other languages
English (en)
Inventor
Robert E Dudley
Original Assignee
Unimed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/651,777 external-priority patent/US6503894B1/en
Application filed by Unimed Pharmaceuticals Inc filed Critical Unimed Pharmaceuticals Inc
Publication of BR0113649A publication Critical patent/BR0113649A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

"PROCESSO PARA AUMENTAR A TESTOSTERONA E AS RELACIONADAS CONCENTRAçõES DE ESTERóIDE EM MULHERES". A presente invenção refere-se a processos, kits e combinações para tratar, prevenir ou reduzir o risco de desenvolvimento de deficiência de testosterona em um mamífero feminino necessitado do mesmo ou relacionados a uma deficiência de testosterona em um mamífero feminino em necessidade da mesma. A presente invenção refere-se também a um processo de administração de um esteróide no caminho sintético da testosterona, por exemplo, testosterona em um mamífero necessitando do mesmo. Ademais, os métodos, kits, combinações e composições podem ser usados em conjunto com outros agentes farmacêuticos eficazes no tratamento, prevenção, ou redução do risco do desenvolvimento de uma deficiência de testosterona. Os processos, kits, combinações e composições podem também ser usados em conjunto com uma quantidade farmaceuticamente eficaz de um hormónio estrogênico, por exemplo, estradiol. Além disso, os processos, kits, combinações e composições podem ser usados em conjunto com uma quantidade farmacologicamente eficaz de um outro esteróide ou agente farmacêutico que aumenta os níveis de testosterona no soro em um mamífero, por exemplo, metiltestosterona.
BR0113649-6A 2000-08-30 2001-08-29 Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres BR0113649A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/651,777 US6503894B1 (en) 2000-08-30 2000-08-30 Pharmaceutical composition and method for treating hypogonadism
US70375300A 2000-11-01 2000-11-01
US29239801P 2001-05-21 2001-05-21
PCT/US2001/027199 WO2002017967A1 (en) 2000-08-30 2001-08-29 Method of increasing testosterone and related steroid concentrations in women

Publications (1)

Publication Number Publication Date
BR0113649A true BR0113649A (pt) 2004-07-20

Family

ID=27404127

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113649-6A BR0113649A (pt) 2000-08-30 2001-08-29 Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres

Country Status (17)

Country Link
EP (1) EP1322336B1 (pt)
JP (1) JP2004507511A (pt)
KR (1) KR20030048021A (pt)
CN (1) CN100349572C (pt)
AU (2) AU8536701A (pt)
BR (1) BR0113649A (pt)
CA (1) CA2419573C (pt)
DK (1) DK1322336T3 (pt)
ES (1) ES2423899T3 (pt)
HK (2) HK1061804A1 (pt)
IL (2) IL154693A0 (pt)
MX (1) MXPA03001859A (pt)
NO (1) NO334991B1 (pt)
NZ (1) NZ536633A (pt)
PL (1) PL360992A1 (pt)
PT (1) PT1322336E (pt)
WO (1) WO2002017967A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
CA2484164C (en) * 2002-03-15 2009-12-29 Unimed Pharmaceuticals, Inc. Androgen pharmaceutical composition and method for treating depression
TWI339122B (en) * 2002-03-15 2011-03-21 Lab Besins Iscovesco Androgen pharmaceutical composition,kit containing the same and method for using the same
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
NZ537360A (en) 2002-06-25 2006-09-29 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
AU2003240299B2 (en) * 2002-06-25 2008-01-31 Acrux Dds Pty. Ltd. Metastable pharmaceutical compositions
AUPS317302A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Metastable pharmaceutical compositions
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
AU2004283431B2 (en) 2003-10-10 2009-09-10 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
WO2006110777A1 (en) * 2005-04-12 2006-10-19 Unimed Pharmaceuticals, Inc. Method of treating or preventing bone deterioration or osteoporosis
KR20080016552A (ko) * 2005-04-13 2008-02-21 유니메드 파마슈티칼스, 인크. 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
ES2607454T3 (es) 2005-06-03 2017-03-31 Acrux Dds Pty Ltd Método y composición para el suministro transdérmico de testosterona
CA2610708C (en) * 2005-06-03 2013-10-08 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
TR201815853T4 (tr) 2005-10-12 2018-11-21 Besins Healthcare Sarl Hipogonadizmin tedavisinde kullanıma yönelik geliştirilmiş testosteron jeli.
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US8882380B2 (en) 2009-12-23 2014-11-11 Colgate-Palmolive Company Oral care system, kit and method
KR101473539B1 (ko) 2009-12-23 2014-12-16 콜게이트-파아므올리브캄파니 구강 관리 시스템
KR101528395B1 (ko) 2009-12-23 2015-06-11 콜게이트-파아므올리브캄파니 구강 관리 시스템
MX2012006290A (es) 2009-12-23 2012-07-03 Colgate Palmolive Co Sistema para el cuidado oral.
US9642862B2 (en) 2010-11-18 2017-05-09 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
AU2019299538A1 (en) * 2018-07-05 2021-01-28 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
IL108371A (en) * 1993-01-19 2009-09-01 Endorech Inc Use of sex steroid precursors to prepare medicaments for treatment of vaginal atrophy
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
CA2280033A1 (en) * 1997-02-07 1998-08-13 Susan Rako Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
CN1172674C (zh) * 1997-11-10 2004-10-27 赛勒吉药物股份有限公司 促进渗透和减少刺激的系统

Also Published As

Publication number Publication date
KR20030048021A (ko) 2003-06-18
MXPA03001859A (es) 2004-05-21
WO2002017967A1 (en) 2002-03-07
PT1322336E (pt) 2013-08-05
CN1466467A (zh) 2004-01-07
CN100349572C (zh) 2007-11-21
NO20030954D0 (no) 2003-02-28
JP2004507511A (ja) 2004-03-11
NZ536633A (en) 2006-03-31
AU8536701A (en) 2002-03-13
NO20030954L (no) 2003-04-28
PL360992A1 (en) 2004-09-20
AU2001285367B2 (en) 2006-05-18
ES2423899T3 (es) 2013-09-25
HK1061804A1 (en) 2004-10-08
CA2419573C (en) 2007-04-03
NO334991B1 (no) 2014-08-18
EP1322336B1 (en) 2013-07-03
EP1322336A1 (en) 2003-07-02
HK1115537A1 (en) 2008-12-05
DK1322336T3 (da) 2013-07-15
IL154693A0 (en) 2003-09-17
CA2419573A1 (en) 2002-03-07
IL154693A (en) 2010-04-15

Similar Documents

Publication Publication Date Title
BR0113649A (pt) Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres
CY1110085T1 (el) Μεθοδος θεραπειας της δυσλειτουργιας στυσης και αυξησης της λιμπιντο στους ανδρες
BRPI0409348B8 (pt) formulações para tratamento de rinossinusite induzida por fungo em um mamífero
BR0107216A (pt) Compostos estroprogestacionais tópicos com efeito sistêmico
BR9910851A (pt) Composição de tratamento para os cabelos.
BRPI0110914B8 (pt) 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
BR0016012A (pt) Implante farmacêutico contendo componentes de liberação imediata e de liberação prolongada, além de processo de administração
BR0311939A (pt) composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico
BR0212374A (pt) Oxintomodulina para a prevenção ou para o tratamento do excesso de peso
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BR0214184A (pt) Composições que contêm óleos que possuem gravidade especìfica mais alta que a gravidade especìfica da água
HK1071521A1 (en) Use of a composition comprising cis-clomiphene andtrans-clomiphene in the preparation of a medicament for increasing serum levels of testosterone
BRPI0611443B8 (pt) medicamento compreendendo gestágeno e/ou estrógeno e 5-metil-(6s)-tetrahidrofolato, seu uso e seu processo de formulação, e kit
BR9914419A (pt) Terapia para melhoria da percepção
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
CA2467237A1 (en) Method of preventing or treating benign gynaecological disorders
BR0113625A (pt) Exemestano como agente de quimioprevenção
BR0111141A (pt) Métodos de tratar a deficiência de androgênio em homens e de tratar distúrbios relacionados com menopausa masculina nos homens
BR0200246A (pt) Tratamento de combinação para a depressão
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BR0104390A (pt) Método para redução de inflamação e eritema
BR9814284A (pt) Composições e métodos para regulação de fagocitose e expressão de icam-1
Ingle et al. Aromatase inhibitors for therapy of advanced breast cancer

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: UNIMED PHARMACEUTICALS, LLC (US)

Free format text: ALTERADO DE: UNIMED PHARMACEUTICALS, INC.

B25G Requested change of headquarter approved

Owner name: UNIMED PHARMACEUTICALS, LLC (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020090070515/RJ DE 21/07/2009.

B25A Requested transfer of rights approved

Owner name: UNIMED PHARMACEUTICALS, LLC (US) , LABORATOIRES BE

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: UNIMED PHARMACEUTICALS, LLC

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.